7v9b
From Proteopedia
(Difference between revisions)
Line 9: | Line 9: | ||
== Function == | == Function == | ||
[[https://www.uniprot.org/uniprot/G9K389_HUMAN G9K389_HUMAN]] | [[https://www.uniprot.org/uniprot/G9K389_HUMAN G9K389_HUMAN]] | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | The transcriptional activity of Forkhead Box O3 (FOXO3a) is inactivated by AKT-mediated phosphorylation on Serine 253 (S253), which enables FOXO3a binding to 14-3-3. Phosphorylated FOXO3a binding to 14-3-3 facilitates the nuclear exclusion of FOXO3a, causing cancer cell proliferation. The FOXO3a/14-3-3 interaction has, therefore, emerged as an important therapeutic target. Here, we report a comprehensive analysis using fluorescence polarization, isothermal titration calorimetry, small-angle X-ray scattering, X-ray crystallography, and molecular dynamics simulations to gain molecular-level insights into the interaction of FOXO3a(pS253) phosphopeptide with 14-3-3epsilon. A high-resolution structure of the fluorophore-labeled FOXO3a(pS253):14-3-3epsilon complex revealed a distinct mode of interaction compared to other 14-3-3 phosphopeptide complexes. FOXO3a(pS253) phosphopeptide showed significant structural difference in the positions of the -3 and -4 Arg residues relative to pSer, compared to that of a similar phosphopeptide, FOXO1(pS256) bound to 14-3-3sigma. Moreover, molecular dynamics studies show that the significant structural changes and molecular interactions noticed in the crystal structure of FOXO3a(pS253):14-3-3epsilon are preserved over the course of the simulation. Thus, this study reveals structural differences between the binding to 14-3-3 isoforms of FOXO1(pS256) versus FOXO3a(pS253), providing a framework for the rational design of isoform-specific FOXO/14-3-3 protein-protein interaction inhibitors for therapy. | ||
+ | |||
+ | Structure of a 14-3-3epsilon:FOXO3a(pS253) Phosphopeptide Complex Reveals 14-3-3 Isoform-Specific Binding of Forkhead Box Class O Transcription Factor (FOXO) Phosphoproteins.,Mathivanan S, Chunchagatta Lakshman PK, Singh M, Giridharan S, Sathish K, Hurakadli MA, Bharatham K, Kamariah N ACS Omega. 2022 Jul 5;7(28):24344-24352. doi: 10.1021/acsomega.2c01700., eCollection 2022 Jul 19. PMID:35874228<ref>PMID:35874228</ref> | ||
+ | |||
+ | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
+ | </div> | ||
+ | <div class="pdbe-citations 7v9b" style="background-color:#fffaf0;"></div> | ||
+ | == References == | ||
+ | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> |
Revision as of 18:59, 7 September 2022
Crystal Structure of 14-3-3 epsilon with FOXO3a peptide
|